OTC Cholesterol Drugs May Be Revisited By FDA In 2000
This article was originally published in The Tan Sheet
Executive Summary
FDA will re-examine the question of potential Rx-to-OTC switches of hypercholesterolemia drugs in 2000, including reexamination of a 1997 guidance finding such drugs inappropriate for over-the-counter sale, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said Dec. 16.
You may also be interested in...
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.